10-Jun-2026      10:29

Wanbury explores new market opportunities for its new APIs

Wanbury announced the company has expanded regulatory submission for launch of new Active Pharmaceuticals Ingredients (APIs).

For Diphenhydramine HCl, company submitted DMF to Malaysia and Singapore.

The Company proposed to explore new market opportunities for Paroxetine HCl in Korea and Latin America by submitting the DMFs.

Company also received formal audit report from MFDS (Korea FDA) for its Patalganga facility stating zero observation for the inspection conducted in April 2026.

News source: Capital Market - Live News